New tech-focused MAHA initiatives will usher in 'new era of convenience,' improve health outcomes, Trump says
The White House revealed new details Wednesday regarding the Trump administration's efforts to advance healthcare technology and partnerships with private-sector technology companies.
The "Make Health Tech Great Again" event was expected to provide more details on how the administration is advancing a "next-generation digital health ecosystem," after securing partnerships with companies including Amazon, Anthropic, Apple, Google, and OpenAI to better share information between patient and providers within Medicare and Medicaid services.
"For decades, bureaucrats and entrenched interests buried health data and blocked patients from taking control of their health," Department of Health and Human Services Secretary Robert F. Kennedy, Jr. said in a statement Wednesday ahead of the event. "That ends today. We're tearing down digital walls, returning power to patients, and rebuilding a health system that serves the people. This is how we begin to Make America Healthy Again."
The Trump administration is partnering with more than 60 companies to bolster how health information is shared electronically, including through the use of apps, and beef up the interoperability of health information networks, according to the Centers for Medicare & Medicaid Services (CMS).
The apps aim to address issues including diabetes and obesity management, and provide beneficiaries with AI assistants to walk through symptoms, provide care options, and assist with scheduling appointments. Other functions that the technology aims to solve are providing digital check-ins to streamline services and cut down on paper intake forms.
The White House event is a follow-up to the request for information notice that the CMS posted in May requesting information from stakeholders on ways to beef up health technology interoperability.
Other technological advances on the health front include plans for CMS to launch an app library on Medicare.gov to best direct beneficiaries to the right digital health tools, according to CMS.
"We have the tools and information available now to empower patients to improve their outcomes and their healthcare experience," CMS Administrator Dr. Mehmet Oz said in a statement Wednesday.
"For too long, patients in this country have been burdened with a healthcare system that has not kept pace with the disruptive innovations that have transformed nearly every other sector of our economy," Oz said. "With the commitments made by these entrepreneurial companies today, we stand ready for a paradigm shift in the U.S. healthcare system for the benefit of patients and providers."
__________________
treasury taken in $150 billion so far due to tarries, says $200 billion expected to be added next month
"Today the dream of easily transportable electronic medical records finally becomes a reality." – Trump
thanked reps from apple, google, Samsung, open ai, Athena health, others…..
says "half the net worth of all of our country" present at MAHA tech event.
President Trump: [16:43:34] For decades, America's health care networks have been overdue for a high tech upgrade, and that's what we're doing. The existing systems are often slow, costly, and incompatible with one another. But with today's announcement, we take a major step to bring health care into the digital age, something that, is absolutely vital. We've got to do it. Moving from clipboards and fax machines into a new era of convenience, profitability and speed and, frankly, better health for people under the leadership of administrator launching the CMS Digital Health team to give health care providers, insurers and software companies the tools they need to empower Americans with a 21st century experience on health. The key breakthrough we've made is getting many of the biggest names in the health care and technology to agree to industrywide standards for electronic medical records. [16:44:38][64.6]
"Moving from clipboards and fax machines into a new era of convenience"
"President Trump: [16:45:04] standards of electronic medical records that we talk about [16:45:08][4.0]
President Trump: [16:45:12] This will allow patients to easily transmit information from one doctor to another, even if they're different networks and using different recordkeeping systems, no matter what system they use, they're all transferable. The new standards will also make it simple for patients to access their own personal health records. [16:45:32][20.2]
President Trump: [16:46:13] instead of filling out the same tedious paperwork at every medical appointment, patients will simply be able to grant their doctors access to their records at the push of a button. Just a button, and you're all set and all the information the doctor needs will be immediately transmitted. The system will be entirely opt in, and there will be no centralized, government run database, which everyone is always concerned about. [16:46:41][28.0]
President Trump: [16:46:40] I'm I'm less concerned than anybody. I say whatever it is, it is. But people are very, very concerned about the personal records. They want to keep them very quiet and that's their choice. I think it's a great thing because it will be. It'll be absolutely quiet. [16:46:57][16.8]
"going to make people live longer and be a lot healthier"
President Trump: [16:47:03] We will save time. We will save money, and most importantly, will save lives. It's just going to make people live longer and be a lot healthier. I think that's really what you're looking to do. [16:47:14][10.4]
--------
RFK:
Speaker 3: [16:49:35] Indonesia today is regarded as the highest flourishing shipping nation on Earth. Since 1990, it has increased the lifespan of its women, eight years of its men by nine years. There's no country that has a record like that. There are two major innovations that allow them to achieve that extraordinary outcome, and one of those was to disincentivize people from eating processed foods. [16:50:06][31.0]
Speaker 3: [16:50:13] The other innovation that really transformed Indonesia was allowing people control of their individual health records on the he showed me the app that they use that everybody in Indonesia has and it shows your height, your weight, your blood type, your BMI, your cardiac markers, your diabetes markers, your cholesterol and any kind of individualized treatments like you had. Or if you go to a doctor in another town, he doesn't do what we have to do here, which is to sit there with a clipboard and a fax machine in order to get your health records. It's available, and it allows them to get better treatment, and it also allows you to make better choices over your life. [16:51:02][49.5]
"allowing people control over their individual health records"
"allows you to make better choices over your life"
Speaker 3: [16:51:43] he ran a a commission to reorganize the Australian health system. And they revolutionized and they vastly improved health in Australia. And he said the single thing that he did that was most important to that transformation was the transparency that occurs when people control their own health records, because it gives people the choice over their own health decisions and their lives. [16:52:10][26.6]
Speaker 3: [16:52:09] It gives them a sense of responsibility and allows them to measure the interventions if they change their diet, if they change their exercise, it can show you how many steps you took today. It can tell you if your glucose is spiking, and all of that information will now be available to American citizens. [16:52:32][22.7]
Companies agreed "voluntarily" to start sharing information
"responsibility and control over their own health care decisions"
Speaker 3: [16:53:22] President Trump gave us instructions that he wanted this to happen within six months. We barely made it under the wall. Everything's a doctor. This is leadership. And within six months, every American is going to be doing it. [16:53:34][12.4]
touts 80% of industry agreed to get rid of prior auth?
_______________
OZ:
Dr. Oz: [16:58:55] today we are making American health technology remarkably great again. We've always been at the leadership. [16:59:01][6.5]
today is 60th anniversary of Medicare/Medicaid
Dr. Oz: [17:00:04] These beautiful programs which are the backbone of the social network, the social, support system of this country, the safety net. They're flailing a bunch of reasons. [17:00:16][12.4]
Dr. Oz: [17:02:20] So it's not just keeping people out of the hospitals, getting them to thrive and flourish. That makes what we're doing so critical today. [17:02:27][7.5]
Dr. Oz: [17:02:52] The average Americans are tired. They're tired of waiting for a doctor's appointment. They're tired of waiting for the surprise of what your hospital bill is going to offer. That's being addressed by one of the president's executive orders. They're tired of waiting for access to their medical records. You own your medical records, they're yours. Why? You can't have access to them is this stunning reality in modern day America. They're also tired of waiting for Washington to take action. And this president early on emphatically stated that wasn't going to happen anymore. And today we made that vision into a reality. [17:03:20][28.3]
"building a robust and safe system" that will protect data "better than we imagined"
"empower Americans to own their own property – which is their medical records"
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
14 minutes ago
- CNBC
Healthy Returns: Medicare, Medicaid will reportedly pilot covering obesity drugs – a potential win for drugmakers
For once, the Trump administration may be giving some drugmakers a reason to celebrate. The Trump administration is planning to experiment with covering costly weight loss drugs under Medicare and Medicaid, the Washington Post reported on Friday. That plan could expand access to millions of Americans with obesity who can't currently afford Novo Nordisk's Wegovy and Eli Lilly's Zepbound, blockbuster GLP-1 drugs that cost around $1,000 per month before insurance. In a statement to CNBC about the plan, the Department of Health and Human Services said all drug coverages undergo a "cost-benefit review." The Centers for Medicare and Medicaid Services "does not comment on potential models or coverage," the department added. The reported plan – if it ultimately takes effect – would be a huge win for Eli Lilly, Novo Nordisk and many Americans. Spotty insurance coverage of obesity drugs remains the biggest barrier to access for patients – and it's choking broader uptake and revenue growth for the two pharmaceutical giants. Many health plans, including Medicare, cover GLP-1s for treatment of diabetes, but not obesity. Medicaid coverage of obesity drugs is limited and varies by state, according to health policy research organization KFF. But it's important to remember that this plan isn't exactly new. In November, the Biden administration proposed having Medicare and Medicaid cover obesity treatments, which would have extended access to roughly 3.4 million Medicare beneficiaries and about 4 million Medicaid recipients. The proposal was controversial at the time, as it would cost taxpayers as much as $35 billion over the next decade, a congressional analysis found. The Trump administration dropped that proposal in April, but said it could reconsider coverage of those drugs in the future. Let's get into what the newest reported iteration of the plan looks like. Under the Trump administration's reported pilot plan, state Medicaid programs and Medicare Part D plans would be able to voluntarily choose to cover Ozempic, Wegovy, Mounjaro and Zepbound for patients for "weight management" purposes. That's according to several Centers for Medicare and Medicaid Services documents obtained by the Post. The plan is expected to start in April 2026 for Medicaid and January 2027 for Medicare plans, the Post reported. It's unclear how exactly the plan will play out, Jared Holz, Mizuho health care equity strategist, said in a note to clients on Friday. Holz said he expects the government to put some coverage parameters in place related to factors like age, body weight, body mass index and other comorbidities, or coexisting chronic health conditions. He also said the pricing of the drugs will be a "major consideration." Holz said he expects the government to pay less than the current list prices of drugs. But having that coverage would expand access and could help drive higher sales volumes, he noted. Another factor to consider is how much the government is willing to crack down on so-called compounding pharmacies, which are allowed in rare cases to sell cheaper, unapproved versions of GLP-1s. The pharmaceutical industry fiercely opposes those knock-off GLP-1s, as their safety and efficacy aren't vetted by regulators and they are, in some cases, illegally sold at scale. Holz said the industry's complaints to the government about compounded GLP-1s have so far "not been met with a widespread shut-down." But overall, Holz said the Trump administration's reported willingness to consider covering obesity drugs is "a slight positive as far as industry sentiment." It's definitely a breath of fresh air for Eli Lilly, Novo Nordisk and other drugmakers – including Amgen, Roche, AstraZeneca and Pfizer – that are hoping to bring their own obesity drugs to market. The last six months have been anything but smooth for the broader industry: The Trump administration has ratcheted up calls for drugmakers to lower U.S. drug prices, overhauled federal health agencies and could impose sweeping tariffs on pharmaceuticals imported into the country any day now. We'll keep watching to see whether this plan gets implemented, so stay tuned for our coverage! Feel free to send any tips, suggestions, story ideas and data to Annika at After reporting its second straight earnings miss and guidance cut, UnitedHealth Group completed its executive sweep by replacing CFO John Rex. Executives on the earnings call admitted to mis-execution in Medicare Advantage and pledged to get back to profitability and win back investor trust. Nearly two years ago it was CVS Health under pressure, after profits in the company's Aetna health insurance division were torpedoed by low Medicare Advantage Star quality ratings. This week, CVS beat and raised its outlook on the strength of its MA program. CEO David Joyner, now one year into the job, told me he feels good about the turnaround at Aetna and its Medicare business. On top of that, the company saw market share gains in its stores, thanks in part to winning over Rite Aid customers. Humana, similarly, has seen progress on its turnaround, but CFO Celeste Mellet told me that all insurers are grappling with pricing plans for next year amid high medical costs. One big cost driver right now, Mellet told CNBC, is oncology drugs, as some expensive therapies are now being used in combination. The next moment of truth for the Medicare Advantage players will come over the next six weeks – when they'll learn the fate of their Star ratings for 2026 plans. Long-time health-care executive Dr. Marc Harrison has stepped down as CEO of General Catalyst's Health Assurance Transformation Company, or HATCo, and has moved into a strategic advisor role, CNBC has confirmed. The venture capital firm brought in Harrison and announced the formation of HATCo in 2023. In a release at the time, General Catalyst said the company would work closely with health system partners, and that it would eventually acquire and operate its own health system. Months later, HATCo announced its plans to buy Summa Health, a nonprofit integrated health system in northeast Ohio. Under its new structure, Summa would become a for-profit organization, and General Catalyst said it would introduce new tech-enabled solutions that aim to make care more accessible and affordable. Buying a health system is an unprecedented move in the venture industry, and the deal wasn't well received by some members of the Ohio community. Hundreds signed a petition urging Summa to remain a nonprofit and to halt negotiations with HATCo. Ohio Attorney General Dave Yost conditionally approved the deal in June, though he outlined a number of "enforceable commitments" as part of the agreement. HATCo will have to notify the Attorney General of transactions that could trigger antitrust concerns for 10 years after the deal closes, for instance. Harrison went to medical school in the late 1980s and has spent most of his career within health systems, most recently as CEO of Intermountain Healthcare. General Catalyst told CNBC that Harrison will continue to provide the firm's CEO, Hemant Taneja, with clinical insights and will remain connected to its ecosystem in his new role. "It became increasingly clear to both Marc and to us that Marc's role would best be accomplished as a strategic advisor to Hemant Taneja as we bring that ambition and vision to life," a General Catalyst spokesperson said. Daryl Tol, the head of General Catalyst's Health Assurance Ecosystem, was promoted to president of HATCo, the spokesperson said. He will spearhead the firm's day-to-day- work with Summa Health leadership. General Catalyst has also appointed Kate Walsh, the former Massachusetts Secretary of Health and Human Services, to HATCo's board. In addition, she will serve as the chair of the board at Summa Health once the transaction closes. "We are grateful for Marc's leadership and collaboration as co-founder and CEO to help get us to this point in the evolution of HATCo, and we look forward to leveraging his invaluable perspective as we continue to progress," the spokesperson said.
New York Post
15 minutes ago
- New York Post
Indian components found in Russian drones used for Putin's war, Ukraine claims
Indian-made components have been discovered in Russian drones used for deadly attacks on Ukraine, one of President Volodymyr Zelensky's top officials has claimed. The Iranian-made Shahed drones containing Indian parts have been involved in attacks along the frontlines and against civilians, Ukrainian presidential chief of staff Andriy Yermak wrote on Telegram. He called on the world to 'deprive Russians of the ability to receive components from other countries and stop the killing of Ukrainians,' according to Kyiv-based Ukrainian news agency UNN. 'Also, buying Russian energy resources is financing the war, which does not contribute to peace,' Yermak added. 3 Indian-made components have reportedly been found in Russian drones used for the war on Ukraine. REUTERS The White House and National Security Council didn't immediately respond to a request for comment from The Post. The drone development comes as President Trump has threatened to slap new tariffs on India if it does not stop purchasing Russian oil. 3 Vladimir Putin has relied on relatively inexpensive Shahed drones for his war in Ukraine. via REUTERS 'India is not only buying massive amounts of Russian Oil, they are then, for much of the Oil purchased, selling it on the Open Market for big profits. They don't care how many people in Ukraine are being killed by the Russian War Machine,' Trump wrote on Truth Social on Monday. Trump added on Friday that he was also seeking to impose new sanctions on Russia and any country that purchases its energy exports like crude oil and electricity. India, as the third-biggest oil importer and consumer in the world, has a high demand and draws one-third of its supply from Russia. A source from the Indian government noted that its purchases have helped balance global oil prices by easing the pressure on supplies from other regions. 3 More than 6,000 Shahed-style drones were launched at Ukraine last month alone. AP The relatively inexpensive Shahed drones that included the Indian-made components have become a crucial part of Vladimir Putin's war on Ukraine since late 2022. Iran initially supplied 2,000 fully assembled drones to Russia, which soon established its own assembly system using Iranian ready-made components, according to Ukraine's Security Service. That number was quickly escalated, with more than 6,000 Shahed-type drones launched by Russia last month alone, according to figures from the Ukrainian air force. With Post wires
The Verge
16 minutes ago
- The Verge
The best iPad deals you can get in August
If you know where to look, it's surprisingly easy to save on an iPad — even outside of major sales events like Amazon Prime Day and Black Friday. Here's an insider tip: skip the Apple Store, where discounts are almost nonexistent. Instead, your best bet is to check third-party retailers like Amazon, Walmart, and Best Buy, which frequently offer deals on everything from the entry-level iPad to the powerhouse iPad Pro, making it possible to snag a bargain any time of the year. Apple's tablet lineup now includes six different iPads, which makes tracking deals across each configuration a full-time job. Fortunately, that's exactly what we're here for. Below, you'll find the best discounts on every current model. Want something for basic web browsing? The entry-level iPad is currently down to $299 ($50 off). Looking for more power to play games and edit videos? The iPad Pro with M4 chip is going for $899 ($100 off). No matter which one you choose, rest assured that every model below is set to receive iPadOS 26 in the fall, which is the most significant update the iPad has seen in 15 years. The 11th-generation iPad remains the most affordable tablet in Apple's lineup. While the newest model isn't drastically different from its 10th-gen predecessor, it does offer a few key differences. One notable change is the increase to 128GB of base storage, up from 64GB. Additionally, the new model features Apple's A16 Bionic chip, providing better overall performance when browsing the web, opening apps, and watching videos. That being said, the base iPad still doesn't support Apple Intelligence despite the faster chip, meaning you can't take advantage of features like the ability to generate images and text. It will, however, support iPadOS 26's windowed multitasking feature when the update arrives later this year. Currently, the 11th-gen iPad starts at $349 with Wi-Fi and 128GB of storage. Upgrading to 256GB or 512GB of storage will run you an extra $100 or $200, respectively, while the LTE model starts at $499. The base model recently dropped to $279 ($70 off) during Amazon's most recent Prime Day event, proving that, if you're patient, it's possible to save a good chunk on the MSRP. That said, there are great deals to be had throughout the year. For example, the aforementioned base configuration is currently down to $299 ($50 off) — its second-best price to date — at Amazon, Walmart, and Best Buy. Alternatively, the 256GB model is $399 ($50 off) at Amazon, Walmart, and Best Buy, while the 512GB variant is available for around $598 ($51 off) at Amazon, Walmart, and Best Buy. While the seventh-gen iPad Mini looks nearly identical to its predecessor, it offers a few notable upgrades, including compatibility with the Apple Pencil Pro. The Pencil Pro brings features like squeeze controls for quick tool switching and a so-called 'barrel roll' function, which lets you change the orientation of your stroke by rotating the stylus. The Mini also includes a newer A17 Pro processor with 8GB of RAM to support Apple Intelligence, and the base storage has increased to 128GB, up from 64GB. Otherwise, it retains many of the hallmarks found on its last-gen predecessor, including an 8.3-inch Liquid Retina display, a Touch ID sensor, and an estimated 10 hours of battery life when browsing on Wi-Fi. The 2024 iPad Mini starts at $499 with 128GB of storage — the same price as the previous generation's 64GB model. If you need more room for all your photos and apps, the 256GB and 512GB versions will set you back $599 and $799, respectively. Want to add cellular? That starts at $649. These are hefty price tags for such a small device, which might have you eyeing the larger iPad Air if you're after more screen for your buck. But if you're loyal to the compact form factor for tasks like reading, the iPad Mini is still the one to beat. The iPad Mini dropped to just $379, an all-time low, during Prime Day; however, the current discounts aren't nearly as dramatic, with the 128GB base model going for $474 ($25 off) at Amazon. You can also pick up the 256GB variant at Amazon and Walmart starting around $569 ($30 off), or the 512GB model at Amazon and B&H Photo for $779 ($20 off). The seventh-gen iPad Air sits between the entry-level iPad and the more powerful iPad Pro. It's available in 11-inch and 13-inch configurations, both of which are powered by Apple's speedy M3 chip and compatible with the latest Apple Intelligence features. The Air also works with the updated Magic Keyboard, which now includes a full row of function keys for controlling volume and screen brightness. There's not a ton that's new with the latest Air compared to the prior model, but the bump in power should allow it to last longer. The 11-inch iPad Air starts at $599, and the 13-inch version comes in at $799. While the starting prices are high, the tablet regularly goes on sale, with the 11-inch Air dipping to as low as $479 during events like Prime Day. Right now, for instance, the 11-inch Air with Wi-Fi and 128GB of storage is on sale at Amazon and Walmart starting at $547.27 (about $52 off). The 256GB version is on sale for $629 ($70 off) at Amazon and B&H Photo, while the 512GB model is down to $811.47 (about $88 off) at B&H Photo. If you're after the larger configuration, the 13-inch model with Wi-Fi and 128GB of storage is currently on sale at Amazon and Walmart for around $725 ($75 off). Meanwhile, Amazon and Walmart are offering the configuration with Wi-Fi and 256GB of storage for $815.73 (about $84 off), while the 512GB variant with Wi-Fi is down to $1,000.88 (about $100 off) at Amazon and Walmart. The seventh-gen iPad Pro is the most impressive tablet in Apple's lineup, one that features the company's latest M4 chip and a crisp, 'Tandem OLED' display. It has dedicated hardware for Apple Intelligence processing, a four-speaker setup for richer sound, and a repositioned front-facing camera along the horizontal edge, so you can keep the device in landscape during video calls. The more advanced tech, however, comes at a high price. The 11-inch iPad Pro starts at $999 — the same price as the latest 13-inch MacBook Air — while the larger 13-inch model starts at $1,200. The good news is that the iPad Pro regularly goes on sale. The 11-inch iPad Pro with 256GB of storage is currently down to $899 ($100 off) at Amazon and B&H Photo, while the 512GB model is down to $1,089.90 (about $109 off) at Amazon. Stepping up to the 1TB model — which will provide you with even more room for apps, photos, and videos — will run you $1,459 ($140 off) at Amazon and Walmart. If you want more screen real estate, the 13-inch model with 256GB is around $1,179 ($120 off) at Amazon and Walmart. Meanwhile, the 512GB model is down to $1,359.86 (about $140 off) at Amazon and Walmart, while the 1TB model is available at Amazon and Walmart for $1,631 ($268 off). You can also grab the 2TB model for $2,084 ($215 off) at Amazon and Walmart. Sign up for Verge Deals to get deals on products we've tested sent to your inbox weekly. Posts from this author will be added to your daily email digest and your homepage feed. See All by Brandon Russell Posts from this topic will be added to your daily email digest and your homepage feed. See All Apple Posts from this topic will be added to your daily email digest and your homepage feed. See All Deals Posts from this topic will be added to your daily email digest and your homepage feed. See All iPad Posts from this topic will be added to your daily email digest and your homepage feed. See All Tech
